332 related articles for article (PubMed ID: 25418145)
1. [Variability in the clinical presentation of Pompe disease in infancy: two case reports and response to treatment with human recombinant enzyme].
Moreno-Medinilla E; Berzosa-López R; Mora-Ramírez MD; Blasco-Alonso J; Martínez-Antón J
Rev Neurol; 2014 Dec; 59(11):503-7. PubMed ID: 25418145
[TBL] [Abstract][Full Text] [Related]
2. [Variability in the clinical presentation of Pompe disease: development following enzyme replacement therapy].
Ley-Martos M; Salado-Reyes MJ; Espinosa-Rosso R; Solera-García J; Jiménez-Jiménez L
Rev Neurol; 2015 Nov; 61(9):416-20. PubMed ID: 26503317
[TBL] [Abstract][Full Text] [Related]
3. [Two new mutations in the gene that codes for acid alpha-glucosidase in an adolescent with late-onset Pompe disease].
Guevara-Campos J; Romeo-Villarroel MA; González-De Guevara L; Escobar V
Rev Neurol; 2013 Sep; 57(6):265-8. PubMed ID: 24008937
[TBL] [Abstract][Full Text] [Related]
4. Novel GAA sequence variant c.1211 A>G reduces enzyme activity but not protein expression in infantile and adult onset Pompe disease.
Nilsson MI; Kroos MA; Reuser AJ; Hatcher E; Akhtar M; McCready ME; Tarnopolsky MA
Gene; 2014 Mar; 537(1):41-5. PubMed ID: 24384324
[TBL] [Abstract][Full Text] [Related]
5. Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk.
Van den Hout JM; Kamphoven JH; Winkel LP; Arts WF; De Klerk JB; Loonen MC; Vulto AG; Cromme-Dijkhuis A; Weisglas-Kuperus N; Hop W; Van Hirtum H; Van Diggelen OP; Boer M; Kroos MA; Van Doorn PA; Van der Voort E; Sibbles B; Van Corven EJ; Brakenhoff JP; Van Hove J; Smeitink JA; de Jong G; Reuser AJ; Van der Ploeg AT
Pediatrics; 2004 May; 113(5):e448-57. PubMed ID: 15121988
[TBL] [Abstract][Full Text] [Related]
6. Genotype, phenotype and treatment outcomes of 17 Malaysian patients with infantile-onset Pompe disease and the identification of 3 novel GAA variants.
Chan MY; Jalil JA; Yakob Y; Wahab SAA; Ali EZ; Khalid MKNM; Leong HY; Chew HB; Sivabalakrishnan JB; Ngu LH
Orphanet J Rare Dis; 2023 Aug; 18(1):231. PubMed ID: 37542277
[TBL] [Abstract][Full Text] [Related]
7. [Clinical sequelae of 17 cases with glycogen storage disease type II/Pompe disease].
Zhang HB; Zhang WM; Qiu JJ; Meng Y; Qiu ZQ
Zhonghua Er Ke Za Zhi; 2012 Jun; 50(6):415-9. PubMed ID: 22931935
[TBL] [Abstract][Full Text] [Related]
8. Long-term follow-up results in enzyme replacement therapy for Pompe disease: a case report.
Del Rizzo M; Fanin M; Cerutti A; Cazzorla C; Milanesi O; Nascimbeni AC; Angelini C; Giordano L; Bordugo A; Burlina AB
J Inherit Metab Dis; 2010 Dec; 33 Suppl 3():S389-93. PubMed ID: 20830524
[TBL] [Abstract][Full Text] [Related]
9. A floppy baby.
Hebert K; Haritos D; Kannikeswaran N
Pediatr Emerg Care; 2015 Jun; 31(6):419-21. PubMed ID: 26035495
[TBL] [Abstract][Full Text] [Related]
10. Infantile-onset glycogen storage disease type II (Pompe disease): report of a case with genetic diagnosis and pathological findings.
Teng YT; Su WJ; Hou JW; Huang SF
Chang Gung Med J; 2004 May; 27(5):379-84. PubMed ID: 15366815
[TBL] [Abstract][Full Text] [Related]
11. A Case of Adult-onset Pompe Disease with Cerebral Stroke and Left Ventricular Hypertrophy.
Hossain MA; Miyajima T; Akiyama K; Eto Y
J Stroke Cerebrovasc Dis; 2018 Nov; 27(11):3046-3052. PubMed ID: 30093193
[TBL] [Abstract][Full Text] [Related]
12. Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers.
Raben N; Fukuda T; Gilbert AL; de Jong D; Thurberg BL; Mattaliano RJ; Meikle P; Hopwood JJ; Nagashima K; Nagaraju K; Plotz PH
Mol Ther; 2005 Jan; 11(1):48-56. PubMed ID: 15585405
[TBL] [Abstract][Full Text] [Related]
13. [Clinical and molecular genetic study on two patients of the juvenile form of Pompe disease in China].
Qiu JJ; Wei M; Zhang WM; Shi HP
Zhonghua Er Ke Za Zhi; 2007 Oct; 45(10):760-4. PubMed ID: 18211760
[TBL] [Abstract][Full Text] [Related]
14. Correction of glycogen storage disease type II by enzyme replacement with a recombinant human acid maltase produced by over-expression in a CHO-DHFR(neg) cell line.
Martiniuk F; Chen A; Donnabella V; Arvanitopoulos E; Slonim AE; Raben N; Plotz P; Rom WN
Biochem Biophys Res Commun; 2000 Oct; 276(3):917-23. PubMed ID: 11027569
[TBL] [Abstract][Full Text] [Related]
15. Gingival overgrowth in Pompe disease: a case report.
de Gijt JP; van Capelle CI; Oosterhuis JW; van der Ploeg AT; van der Wal KG
J Oral Maxillofac Surg; 2011 Aug; 69(8):2186-90. PubMed ID: 21783002
[TBL] [Abstract][Full Text] [Related]
16. A cross-sectional single-centre study on the spectrum of Pompe disease, German patients: molecular analysis of the GAA gene, manifestation and genotype-phenotype correlations.
Herzog A; Hartung R; Reuser AJ; Hermanns P; Runz H; Karabul N; Gökce S; Pohlenz J; Kampmann C; Lampe C; Beck M; Mengel E
Orphanet J Rare Dis; 2012 Jun; 7():35. PubMed ID: 22676651
[TBL] [Abstract][Full Text] [Related]
17. Remarkably low fibroblast acid α-glucosidase activity in three adults with Pompe disease.
Wens SC; Kroos MA; de Vries JM; Hoogeveen-Westerveld M; Wijgerde MG; van Doorn PA; van der Ploeg AT; Reuser AJ
Mol Genet Metab; 2012 Nov; 107(3):485-9. PubMed ID: 23000108
[TBL] [Abstract][Full Text] [Related]
18. A new assay for fast, reliable CRIM status determination in infantile-onset Pompe disease.
Wang Z; Okamoto P; Keutzer J
Mol Genet Metab; 2014 Feb; 111(2):92-100. PubMed ID: 24044919
[TBL] [Abstract][Full Text] [Related]
19. Infantile Pompe disease: clinical and genetic characteristics with an experience of enzyme replacement therapy.
Cho A; Kim SJ; Lim BC; Hwang H; Park JD; Kim GB; Jin DK; Lee J; Ki CS; Kim KJ; Hwang YS; Chae JH
J Child Neurol; 2012 Mar; 27(3):319-24. PubMed ID: 21940687
[TBL] [Abstract][Full Text] [Related]
20. Enzyme replacement therapy for infantile Pompe disease during the critical period and identification of a novel mutation.
But WM; Lee SH; Chan AO; Lau GT
Hong Kong Med J; 2009 Dec; 15(6):474-7. PubMed ID: 19966354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
